Table 1. Patient, tumour, and preoperative treatment variables in patients undergoing preoperative chemotherapy±radiation therapy for gastric and gastrooesophageal junction adenocarcinoma, followed by R0 resection.
|
Number (%)
|
|||
|---|---|---|---|
| Variable | Non-pCR patients (n=549) | pCR patients (n=60) | P-valuea |
| Age (median, IQR) | 62 (54–69) | 64 (56–69) | 0.18b |
| Preoperative BMI (median, IQR) | 27 (24–30) | 28 (25–32) | 0.04b |
| Gender | |||
| Male | 403 (73) | 52 (87) | 0.02 |
| Female | 146 (27) | 8 (13) | |
| Race | |||
| Caucasian | 487 (89) | 57 (95) | |
| African-American | 24 (4) | 1 (2) | 0.64 |
| Asian/Pacific Islander | 31 (6) | 2 (3) | |
| Other/unknown | 7 (1) | 0 (0) | |
| Tumour location | |||
| GEJ | 312 (57) | 47 (78) | |
| Gastric, proximal | 74 (13) | 6 (10) | |
| Gastric, body | 71 (13) | 4 (7) | 0.02 |
| Gastric, distal | 85 (15) | 3 (5) | |
| Gastric, diffuse | 7 (1) | 0 (0) | |
| Pretreatment EUS T-stage | |||
| T1 | 4 (1) | 0 (0) | |
| T2 | 72 (13) | 10 (17) | |
| T3 | 447 (81) | 50 (83) | 0.43 |
| T4 | 15 (3) | 0 (0) | |
| Not performed | 11 (2) | 0 (0) | |
| Histology – Lauren classification | |||
| Diffuse | 169 (31) | 19 (32) | |
| Intestinal | 333 (61) | 39 (65) | 0.62 |
| Mixed | 47 (9) | 2 (3) | |
| Histology – differentiation | |||
| Well | 12 (2) | 3 (5) | |
| Moderate | 207 (38) | 14 (23) | 0.25 |
| Poor | 330 (60) | 43 (72) | |
| Preoperative chemotherapy regimen | |||
| 5-FU and platinum based | 221 (39) | 23 (34) | |
| Platinum based | 157 (27) | 15 (22) | 0.0007 |
| Taxane based | 130 (23) | 28 (41) | |
| Other | 65 (11) | 2 (3) | |
| Preoperative radiation treatment | |||
| Yes | 233 (42) | 47 (78) | <0.0001 |
Abbreviations: 5-FU=5-fluorouracil; BMI=body mass index; GEJ=gastrooesophageal junction; IQR=interquartile range; pCR=pathologic complete response; EUS=endoscopic ultrasound.
a
χ2 text, except where otherwise noted by ‘b’.
b
Wilcoxon rank sum test with continuity correction. Bold values indicate significant differences.